Latest Breaking News On - செல்ஜீன் கார்ப் - Page 8 : comparemela.com
Ovarian Cancer Market 2021 Global Analysis, Growth, Size, Share, Trends, Forecast to 2026
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Ovarian Cancer Market 2021 Global Analysis, Growth, Size, Share, Trends, Forecast to 2026
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Provided by Dow Jones By Matt Grossman Bristol Myers Squibb Co. Thursday logged a fourth-quarter adjusted profit as higher sales of Eliquis and Opdivo, as well as medications it acquired in an acquisition, pushed revenue higher. The New York City-based pharmaceutical company logged a loss of $4.45 a share, compared with a loss of 55 cents a share in the year-ago quarter. The net loss attributable to the company was $10.03 billion, compared with a net loss of $1.06 billion in the year-ago quarter. The past quarter s results included a $11.44 billion in-process research-and-development charge related to Bristol s acquisition of MyoKardia Inc., a pharmaceutical company focused on cardiovascular treatments, which closed in the quarter.
Endeavor BioMedicines raises $62 million to combat pulmonary disease
A new startup has officially emerged from stealth with the raise of its $62 million Series A funding round. Endeavor BioMedicines is led by co-founder and CEO John Hood, who previously led Impact Biomedicines, and its new funding comes from Omega Funds and Longitude Capital, as well as the company’s own management team. Endeavor is also co-founded by Miguel de los Rios, who serves as its chief science officer and who was previously CEO of Rift Biotherapeutics.
Endeavor’s goal is to develop treatments specifically to address pulmonary disease, and the startup is putting its funding toward two phase 2 clinical trials that will seek to determine whether their therapeutic candidate can reverse or slow the progression of idiopathic pulmonary fibrosis (IPF), a very common type of pulmonary fibrosis that results in long tissue scarring that causes difficulty in breathing for affected patients.
vimarsana © 2020. All Rights Reserved.